| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Africa's lessons of resiliency and preparedness after Ebola
|
Balakrishnan, Vijay Shankar
|
|
|
24 |
2 |
p. 128
|
artikel
|
| 2 |
A new dawn for malaria prevention
|
The Lancet Infectious Diseases,
|
|
|
24 |
2 |
p. 107
|
artikel
|
| 3 |
A toolkit of people-centred approaches to address AMR
|
Jesudason, Timothy
|
|
|
24 |
2 |
p. e85
|
artikel
|
| 4 |
Boostability after single-visit pre-exposure prophylaxis with rabies vaccine: a randomised controlled non-inferiority trial
|
Overduin, Lisanne A
|
|
|
24 |
2 |
p. 206-216
|
artikel
|
| 5 |
Boosting pathogen genomics and bioinformatics workforce in Africa
|
Onywera, Harris
|
|
|
24 |
2 |
p. e106-e112
|
artikel
|
| 6 |
Brain abscess caused by Listeria monocytogenes and Toxoplasma gondii
|
Goudy, Pierre
|
|
|
24 |
2 |
p. e136
|
artikel
|
| 7 |
ChatGPT neglects a neglected disease
|
Nacher, Mathieu
|
|
|
24 |
2 |
p. e76
|
artikel
|
| 8 |
Child-friendly rifapentine formulation is a game changer
|
Holt, Ed
|
|
|
24 |
2 |
p. e84
|
artikel
|
| 9 |
Clarifying pertussis in Denmark
|
Dalby, Tine
|
|
|
24 |
2 |
p. e77
|
artikel
|
| 10 |
Correction to Lancet Infect Dis 2022; 22: 1681–93
|
|
|
|
24 |
2 |
p. e83
|
artikel
|
| 11 |
Correction to Lancet Infect Dis 2023; 23: 683–95
|
|
|
|
24 |
2 |
p. e83
|
artikel
|
| 12 |
Correction to Lancet Infect Dis 2023; 23: e520–32
|
|
|
|
24 |
2 |
p. e83
|
artikel
|
| 13 |
Correction to Lancet Infect Dis 2023; published online Nov 24. https://doi.org/10.1016/S1473-3099(23)00505-4
|
|
|
|
24 |
2 |
p. e83
|
artikel
|
| 14 |
Correction to Lancet Infect Dis 2023; published online Nov 20. https://doi.org/10.1016/S1473-3099(23)00500-5
|
|
|
|
24 |
2 |
p. e83
|
artikel
|
| 15 |
Correction to Lancet Infect Dis 2023; published online Oct 16. https://doi.org/10.1016/S1473-3099(23)00502-9
|
|
|
|
24 |
2 |
p. e83
|
artikel
|
| 16 |
Determinants of piperaquine-resistant malaria in South America
|
Mok, Sachel
|
|
|
24 |
2 |
p. 114-116
|
artikel
|
| 17 |
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries
|
Olbrich, Laura
|
|
|
24 |
2 |
p. 140-149
|
artikel
|
| 18 |
Diagnostics for childhood tuberculosis: a marathon rather than a sprint
|
Togun, Toyin Omotayo
|
|
|
24 |
2 |
p. 110-112
|
artikel
|
| 19 |
Diphtheria outbreak in west Africa
|
Samarasekera, Udani
|
|
|
24 |
2 |
p. e87
|
artikel
|
| 20 |
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis
|
Commons, Robert J
|
|
|
24 |
2 |
p. 172-183
|
artikel
|
| 21 |
Efficacy and safety of moxidectin against strongyloidiasis
|
Luvira, Viravarn
|
|
|
24 |
2 |
p. 118-119
|
artikel
|
| 22 |
Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial
|
Sprecher, Viviane P
|
|
|
24 |
2 |
p. 196-205
|
artikel
|
| 23 |
Endocarditis guidelines: call for an interdisciplinary approach
|
Koch, Till
|
|
|
24 |
2 |
p. e75
|
artikel
|
| 24 |
Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure
|
Yang, Sijie
|
|
|
24 |
2 |
p. e70-e72
|
artikel
|
| 25 |
Gerd Sutter
|
Bagcchi, Sanjeet
|
|
|
24 |
2 |
p. 122
|
artikel
|
| 26 |
Going beyond a market-driven global health framework
|
Balakrishnan, Vijay Shankar
|
|
|
24 |
2 |
p. 126
|
artikel
|
| 27 |
Good news for travellers, but what do rabies vaccines say about global health?
|
Hampson, Katie
|
|
|
24 |
2 |
p. 119-121
|
artikel
|
| 28 |
Growing up with polio
|
Das, Manjulika
|
|
|
24 |
2 |
p. 127
|
artikel
|
| 29 |
How to tailor recommendations on the treatment of multi-drug resistant Gram-negative infections at country level integrating antibiotic stewardship principles within the GRADE-ADOLOPMENT framework
|
Carrara, Elena
|
|
|
24 |
2 |
p. e113-e126
|
artikel
|
| 30 |
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
|
Marking, Ulrika
|
|
|
24 |
2 |
p. e80-e81
|
artikel
|
| 31 |
Impact of piperaquine resistance in Plasmodium falciparum on malaria treatment effectiveness in The Guianas: a descriptive epidemiological study
|
Florimond, Celia
|
|
|
24 |
2 |
p. 161-171
|
artikel
|
| 32 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
24 |
2 |
p. e91
|
artikel
|
| 33 |
Jue Liu—using big data to tackle infectious diseases
|
Kirby, Tony
|
|
|
24 |
2 |
p. 123
|
artikel
|
| 34 |
Millions of dollars pledged at COP28 to fight NTDs
|
Venkatesan, Priya
|
|
|
24 |
2 |
p. e88
|
artikel
|
| 35 |
Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications
|
Pinnetti, Carmela
|
|
|
24 |
2 |
p. e127-e135
|
artikel
|
| 36 |
Noma a neglected tropical disease, says WHO
|
Burki, Talha
|
|
|
24 |
2 |
p. e89-e90
|
artikel
|
| 37 |
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
|
Wajja, Anne
|
|
|
24 |
2 |
p. e78-e79
|
artikel
|
| 38 |
Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19
|
Gottlieb, Robert L
|
|
|
24 |
2 |
p. 108-110
|
artikel
|
| 39 |
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
|
Fan, Xiaohong
|
|
|
24 |
2 |
p. 129-139
|
artikel
|
| 40 |
Prevention and post-exposure management of occupational exposure to Ebola virus
|
Moso, Michael A
|
|
|
24 |
2 |
p. e93-e105
|
artikel
|
| 41 |
Primaquine dose and the risk of haemolysis and Plasmodium vivax recurrence: pooling the available data to reassure the unconvinced
|
Millat-Martínez, Pere
|
|
|
24 |
2 |
p. 116-118
|
artikel
|
| 42 |
Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
|
Rajasekhar, Megha
|
|
|
24 |
2 |
p. 184-195
|
artikel
|
| 43 |
Remembering women in the fight against AIDS
|
Bisbas, Georgia
|
|
|
24 |
2 |
p. 124
|
artikel
|
| 44 |
Research in brief
|
Devi, Sharmila
|
|
|
24 |
2 |
p. e92
|
artikel
|
| 45 |
Roadmap to tackle tuberculosis in children and adolescents
|
Bagcchi, Sanjeet
|
|
|
24 |
2 |
p. e86
|
artikel
|
| 46 |
Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial
|
Walsh, Mary-Claire R
|
|
|
24 |
2 |
p. 150-160
|
artikel
|
| 47 |
Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study
|
Hansen, Christian Holm
|
|
|
24 |
2 |
p. e73-e74
|
artikel
|
| 48 |
The big fail
|
Burki, Talha
|
|
|
24 |
2 |
p. 125
|
artikel
|
| 49 |
The Dengue-in-Dhaka Initiative: results from a phase 2 trial evaluating the TV005 tetravalent dengue vaccine in Bangladesh
|
Wilder-Smith, Annelies
|
|
|
24 |
2 |
p. 112-113
|
artikel
|
| 50 |
Virological characteristics of the SARS-CoV-2 JN.1 variant
|
Kaku, Yu
|
|
|
24 |
2 |
p. e82
|
artikel
|
Tijdschrift beschrijving